乐普医疗：子公司与Sidera Bio Aps.签署授权许可协议

Core Viewpoint - Lepu Medical (300003) announced the licensing of its proprietary MWN105 injection to Denmark's Sidera Bio Aps, granting exclusive rights for development and commercialization outside Greater China [1] Group 1: Licensing Agreement - Lepu Medical's subsidiary, Shanghai Minwei Biotechnology Co., Ltd., will license MWN105 injection to Sidera Bio Aps for a fee [1] - Sidera Bio Aps will receive exclusive rights to develop and commercialize MWN105 injection globally, excluding Greater China [1] Group 2: Financial Aspects - As part of the licensing deal, Shanghai Minwei Biotechnology will acquire a 9.99% equity stake in Sidera Bio Aps [1] - The agreement includes receiving licensing fees from Sidera Bio Aps for the MWN105 injection [1]